Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
2.730
+0.180 (7.06%)
At close: May 28, 2025, 4:00 PM
2.600
-0.130 (-4.76%)
After-hours: May 28, 2025, 5:29 PM EDT
Aquestive Therapeutics Revenue
Aquestive Therapeutics had revenue of $8.72M in the quarter ending March 31, 2025, a decrease of -27.65%. This brings the company's revenue in the last twelve months to $54.23M, up 5.29% year-over-year. In the year 2024, Aquestive Therapeutics had annual revenue of $57.56M with 13.80% growth.
Revenue (ttm)
$54.23M
Revenue Growth
+5.29%
P/S Ratio
4.34
Revenue / Employee
$381,887
Employees
142
Market Cap
271.17M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 57.56M | 6.98M | 13.80% |
Dec 31, 2023 | 50.58M | 2.90M | 6.09% |
Dec 31, 2022 | 47.68M | -3.15M | -6.20% |
Dec 31, 2021 | 50.83M | 4.98M | 10.87% |
Dec 31, 2020 | 45.85M | -6.76M | -12.85% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2006 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AQST News
- 15 days ago - Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 24 days ago - Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential - Seeking Alpha
- 27 days ago - Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET - GlobeNewsWire
- 7 weeks ago - Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium - GlobeNewsWire
- 2 months ago - Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy - Seeking Alpha
- 2 months ago - Aquestive Therapeutics, Inc. (AQST) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire